Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04421404 · ClinicalTrials.gov registry record · Phase 2
Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients
A Phase 2 study, sponsored by Priscilla Hsue, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT04421404 is a Phase 2 study that has completed, run by Priscilla Hsue, MD. The registered enrollment target is 34 participants.
The verdict
NCT04421404, a Phase 2 study, has completed, sponsored by Priscilla Hsue, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
The purpose of this study assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma in hospitalized patients with acute respiratory symptoms up to 14 days after the onset of initial symptoms.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL COVID-19 Convalescent Plasma (CCP)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2020-06-09 |
| Est. Completion | 2021-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04421404
The ClinicalTrials.gov registry entry for NCT04421404 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Priscilla Hsue, MD, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04421404 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04421404 about?
NCT04421404 is a clinical study titled "Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients". The purpose of this study assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma in hospitalized patients with acute respiratory symptoms up to 14 days after the onset of initial symptoms.
What is the current status of trial NCT04421404?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2020-06-09. Estimated completion is 2021-04-30.
What interventions are being tested in trial NCT04421404?
The interventions under investigation include: Placebo (BIOLOGICAL), COVID-19 Convalescent Plasma (CCP) (BIOLOGICAL).
Who is sponsoring clinical trial NCT04421404?
This trial is sponsored by Priscilla Hsue, MD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.